HALO

HALOZYME THERAPEUTICS, INC.

NasdaqHealthcareBiological Products, (No Diagnostic Substances)

Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Latest filingSep 02, 2026Most recent Form 4
Total buying$00 buys
Total selling$627M11 sells
Net open-market-$627M2 insiders
Open-market mix
Buy vs sell distribution by transaction count
11 transactions
0 buys0%·100%11 sells

Insider activity report

Monthly open-market purchase and sale counts
Buys Sells
1580-8-15transactionsAug 2026 sells: 11 transactions · $627M11AugSep

Transaction codes

By Form 4 transaction code in selected period
19transactions
  • S · Open-market sells · dominant11 · 58%
  • M · Option exercise6 · 32%
  • A · Grants / awards2 · 11%

Activity by reported role

A joint filing can contribute to multiple roles
19transactions
  • PRES · dominant17 · 89%
  • Director2 · 11%

Distinct insiders active

Reporting-owner CIKs by month · peak Aug 2026 (1)
Aug 2026Sep 2026
2distinct insiders in 2 months

Reported Holdings After

Separated by insider, security, and ownership type
Torley HelenCommon Stock · Direct
787.8k767.8kAug 17, 2026 · 767,780 shares owned afterAug 17, 2026 · 787,780 shares owned afterAug 17, 2026 · 775,280 shares owned afterAug 17, 2026 · 784,280 shares owned afterAug 17, 2026 · 786,380 shares owned afterAug 17, 2026 · 786,880 shares owned afterAug 18, 2026 · 777,180 shares owned afterAug 18, 2026 · 787,780 shares owned afterAug 18, 2026 · 782,077 shares owned afterAug 18, 2026 · 767,780 shares owned afterAug 19, 2026 · 770,980 shares owned afterAug 19, 2026 · 767,780 shares owned afterAug 19, 2026 · 780,580 shares owned afterAug 19, 2026 · 787,780 shares owned afterAug 17, 2026Aug 19, 2026
787,780Aug 19, 2026
Torley HelenOption to Purchase Common Stock · Direct
181.6k141.6kAug 17, 2026 · 181,552 shares owned afterAug 18, 2026 · 161,552 shares owned afterAug 19, 2026 · 141,552 shares owned afterAug 17, 2026Aug 19, 2026
141,552Aug 19, 2026
Appelhans DannielleOption to Purchase Common Stock · Direct
1.8k1.8kSep 01, 2026 · 1,778 shares owned afterSep 01, 2026Sep 01, 2026
1,778Sep 01, 2026
Appelhans DannielleRestricted Stock Units · Direct
1.2k1.2kSep 01, 2026 · 1,161 shares owned afterSep 01, 2026Sep 01, 2026
1,161Sep 01, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells red
0 active days
Aug 04Sep 04
LessMore

Filing detail checks

Secondary metrics for the selected period
Largest buy-
Largest sale$102M
10b5-1 detected17
Amended rows0

Filing-only signals

Deterministic matches in the selected period

HALO transaction history

Filters apply within this company and selected period by default
Reset
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date

No transactions match your filters

Once the backend ingests and parses SEC filings, they will appear here. Try removing a filter or picking a wider date range.

HALOZYME THERAPEUTICS, INC. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at HALOZYME THERAPEUTICS, INC.?

Appelhans Dannielle, Torley Helen.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Torley Helen reported a sale on Aug 19, 2026 valued at $34.4M. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $6,275,591.92. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.